Joshua M Mesfin
Overview
Explore the profile of Joshua M Mesfin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hunter J, Mesfin J, Ahmed T, Chen A, Reimold K, Hancko A, et al.
JACC Basic Transl Sci
. 2024 Apr;
9(3):322-338.
PMID: 38559631
This study evaluates the effectiveness of myocardial matrix (MM) hydrogels in mitigating negative right ventricular (RV) remodeling in a rat model of RV heart failure. The goal was to assess...
2.
Wang R, Mesfin J, Karkanitsa M, Ungerleider J, Zelus E, Zhang Y, et al.
NPJ Regen Med
. 2023 Sep;
8(1):53.
PMID: 37730736
Bioactive immunomodulatory biomaterials have shown promise for influencing the immune response to promote tissue repair and regeneration. Macrophages and T cells have been associated with this response; however, other immune...
3.
Liang Y, Sullivan H, Carrow K, Mesfin J, Korpanty J, Worthington K, et al.
J Am Chem Soc
. 2023 May;
145(20):11185-11194.
PMID: 37184379
Nanoparticles that undergo a localized morphology change to target areas of inflammation have been previously developed but are limited by their lack of biodegradability. In this paper, we describe a...
4.
Chen A, Mesfin J, Gianneschi N, Christman K
Adv Mater
. 2023 Mar;
36(43):e2300603.
PMID: 36989469
Each year, nearly 19 million people die of cardiovascular disease with coronary heart disease and myocardial infarction (MI) as the leading cause of the progression of heart failure. Due to...
5.
Stopfer L, Rettko N, Leddy O, Mesfin J, Brown E, Winski S, et al.
Proc Natl Acad Sci U S A
. 2022 Dec;
119(49):e2208900119.
PMID: 36454758
Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma-namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies-may offer an improved survival benefit by overcoming limitations associated with any individual...
6.
Wang R, Mesfin J, Hunter J, Cattaneo P, Guimaraes-Camboa N, Braden R, et al.
Acta Biomater
. 2022 Aug;
152:47-59.
PMID: 36041648
As the native regenerative potential of adult cardiac tissue is limited post-injury, stimulating endogenous repair mechanisms in the mammalian myocardium is a potential goal of regenerative medicine therapeutics. Injection of...
7.
Stopfer L, Mesfin J, Joughin B, Lauffenburger D, White F
Nat Commun
. 2020 Jun;
11(1):2760.
PMID: 32488085
Peptides bound to class I major histocompatibility complexes (MHC) play a critical role in immune cell recognition and can trigger an antitumor immune response in cancer. Surface MHC levels can...